Gravitate Health FHIR Implementation Guide (FHIR R4)
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide (FHIR R4)
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide (FHIR R4), published by . This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/hl7-eu/gravitate-health-ips/ and changes regularly. See the Directory of published versions
{
"resourceType" : "Bundle",
"id" : "gravitate-example-testing-scenario-bundle",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/ips/StructureDefinition/Bundle-uv-ips"
]
},
"identifier" : {
"system" : "https://www.gravitatehealth.eu/sid/doc",
"value" : "example-test-scenario-ips-1"
},
"type" : "document",
"timestamp" : "2021-04-18T09:22:00+02:00",
"entry" : [
{
"fullUrl" : "https://myserver.org/Composition/gravitate-example-testing-scenario-composition",
"resource" : {
"resourceType" : "Composition",
"id" : "gravitate-example-test-scenario",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/ips/StructureDefinition/Composition-uv-ips"
]
},
"text" : {
"status" : "extensions",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><a name=\"Composition_gravitate-example-test-scenario\"> </a>\n \n\n \n <b>Id:</b>\n gravitate-example-test-scenario\n <br/>\n \n <b>status:</b>\n Final\n <br/>\n \n <b>Type:</b>\n Patient summary Document\n <br/>\n \n <b>Subject:</b>\n <a/>\n \n\n <br/>\n <b>Sections:</b>\n <br/>\n\n <ul>\n \n <li>\n\n Medication Summary\n\n </li>\n <ul>\n\n \n\n <li>\n\n Humalog Mix50 Insulin KwikPen, 3ml pre-fill\n\n </li>\n \n\n <li>\n\n Monuril 3 g granules for oral solution\n\n </li>\n \n </ul>\n\n \n <li>\n\n Allergies and Intolerances\n\n </li>\n <ul>\n\n \n </ul>\n\n \n <li>\n\n Problem List\n\n </li>\n <ul>\n\n \n </ul>\n\n \n\n </ul>\n\n \n\n</div>"
},
"status" : "final",
"type" : {
"coding" : [
{
"system" : "http://loinc.org",
"code" : "60591-5",
"display" : "Patient summary Document"
}
]
},
"subject" : {
"reference" : "Patient/gravitate-example-testing-scenario-patient"
},
"date" : "2018-07-10T15:22:00+02:00",
"author" : [
{
"display" : "Gravitate-Health"
}
],
"title" : "International Patient Summary",
"confidentiality" : "N",
"section" : [
{
"title" : "Medication Summary",
"code" : {
"coding" : [
{
"system" : "http://loinc.org",
"code" : "10160-0",
"display" : "Hx of Medication use"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><table><thead><tr><th>Brand Name</th><th>MAN</th><th>Active Substance</th><th>Common Name</th><th>ATC</th><th>Strength</th><th>Dose Form</th><th>RoA</th></tr></thead><tbody><tr><td>Humalog Mix50 Insulin KwikPen, 3ml pre-fill</td><td>EU/1/96/007/035</td><td>insulin lispro (GFX7QIS1II)</td><td>insulin lispro</td><td>A10AD04</td><td>100 U/ml</td><td>Suspension for injection</td><td>Subcutaneous use</td></tr><tr><td>Monuril 3 g granules for oral solution</td><td>PL31654/0006</td><td>FOSFOMYCIN (2N81MY12TE)</td><td>fosfomycin</td><td>J01XX01</td><td>3 g (as trometamol: 5.631g/sachet)</td><td>Granules for oral solution</td><td>Oral use</td></tr></tbody></table></div>"
},
"entry" : [
{
"reference" : "MedicationStatement/gravitate-example-testing-scenario-medstat1",
"display" : "Humalog Mix50 Insulin KwikPen, 3ml pre-fill"
},
{
"reference" : "MedicationStatement/gravitate-example-testing-scenario-medstat2",
"display" : "Monuril 3 g granules for oral solution"
}
]
},
{
"title" : "Allergies and Intolerances",
"code" : {
"coding" : [
{
"system" : "http://loinc.org",
"code" : "48765-2",
"display" : "Allergies and adverse reactions Document"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\" lang=\"en-NZ\" xml:lang=\"en-NZ\">There is no information available regarding the subject's allergy conditions.</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "unavailable",
"display" : "Unavailable"
}
],
"text" : "No information available"
}
},
{
"title" : "Problem List",
"code" : {
"coding" : [
{
"system" : "http://loinc.org",
"code" : "11450-4",
"display" : "Problem list - Reported"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\" lang=\"en-NZ\" xml:lang=\"en-NZ\">There is no information available about the subject's health problems or disabilities.</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "unavailable",
"display" : "Unavailable"
}
],
"text" : "No information available"
}
}
]
}
},
{
"fullUrl" : "https://myserver.org/Patient/gravitate-example-testing-scenario-patient",
"resource" : {
"resourceType" : "Patient",
"id" : "gravitate-example-testing-scenario-patient",
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Example Test Scenario Gravitate, Female, 75 years old (1946-05-05)</div>"
},
"identifier" : [
{
"system" : "https://www.gravitatehealth.eu/sid/doc",
"value" : "example-test-scenario-1"
}
],
"active" : true,
"name" : [
{
"family" : "Gravitate",
"given" : [
"Example Test Scenario"
]
}
],
"gender" : "female",
"birthDate" : "1946-05-05"
}
},
{
"fullUrl" : "https://myserver.org/MedicationStatement/gravitate-example-testing-scenario-medstat1",
"resource" : {
"resourceType" : "MedicationStatement",
"id" : "gravitate-example-testing-scenario-medstat1",
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><a name=\"MedicationStatement_gravitate-example-testing-scenario-medstat1\"> </a><p class=\"res-header-id\"><b>Generated Narrative: MedicationStatement gravitate-example-testing-scenario-medstat1</b></p><a name=\"gravitate-example-testing-scenario-medstat1\"> </a><a name=\"hcgravitate-example-testing-scenario-medstat1\"> </a><a name=\"gravitate-example-testing-scenario-medstat1-en-US\"> </a><p><b>status</b>: Active</p><p><b>medication</b>: <a href=\"Bundle-gravitate-Pedro.html#Medication_9d7be868-8264-4d94-ad04-ef04ecc92e52\">Dovato 50 mg/300 mg (Dolutegravir/ Lamivudine) tablets</a></p><p><b>subject</b>: <a href=\"Bundle-gravitate-example-testing-scenario-bundle.html#Patient_gravitate-example-testing-scenario-patient\">Example Test Scenario Gravitate</a></p><h3>Dosages</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Route</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{http://standardterms.edqm.eu 20053000}\">Oral use</span></td></tr></table></div>"
},
"status" : "active",
"medicationReference" : {
"reference" : "Medication/9d7be868-8264-4d94-ad04-ef04ecc92e52",
"display" : "Dovato 50 mg/300 mg (Dolutegravir/ Lamivudine) tablets"
},
"subject" : {
"reference" : "Patient/gravitate-example-testing-scenario-patient",
"display" : "Example Test Scenario Gravitate"
},
"dosage" : [
{
"route" : {
"coding" : [
{
"system" : "http://standardterms.edqm.eu",
"code" : "20053000",
"display" : "Oral use"
}
]
}
}
]
}
},
{
"fullUrl" : "https://myserver.org/MedicationStatement/gravitate-example-testing-scenario-medstat2",
"resource" : {
"resourceType" : "MedicationStatement",
"id" : "gravitate-example-testing-scenario-medstat2",
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><a name=\"MedicationStatement_gravitate-example-testing-scenario-medstat2\"> </a><p class=\"res-header-id\"><b>Generated Narrative: MedicationStatement gravitate-example-testing-scenario-medstat2</b></p><a name=\"gravitate-example-testing-scenario-medstat2\"> </a><a name=\"hcgravitate-example-testing-scenario-medstat2\"> </a><a name=\"gravitate-example-testing-scenario-medstat2-en-US\"> </a><p><b>status</b>: Active</p><p><b>medication</b>: <a href=\"Bundle-gravitate-Alicia.html#Medication_9d7be868-8264-4d94-ad04-ef04ecc92i99\">BIKTARVY Bictegravir/Emtricitabine/Tenofovir Alafenamide 1 t QD</a></p><p><b>subject</b>: <a href=\"Bundle-gravitate-example-testing-scenario-bundle.html#Patient_gravitate-example-testing-scenario-patient\">Example Test Scenario Gravitate</a></p><h3>Dosages</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Route</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{http://standardterms.edqm.eu 20053000}\">Oral use</span></td></tr></table></div>"
},
"status" : "active",
"medicationReference" : {
"reference" : "Medication/9d7be868-8264-4d94-ad04-ef04ecc92i99",
"display" : "BIKTARVY Bictegravir/Emtricitabine/Tenofovir Alafenamide 1 t QD"
},
"subject" : {
"reference" : "Patient/gravitate-example-testing-scenario-patient",
"display" : "Example Test Scenario Gravitate"
},
"dosage" : [
{
"route" : {
"coding" : [
{
"system" : "http://standardterms.edqm.eu",
"code" : "20053000",
"display" : "Oral use"
}
]
}
}
]
}
}
]
}
IG © 2021+ . Package hl7.eu.fhir.gh-ips#0.1.0 based on FHIR 4.0.1. Generated 2024-10-01
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
